** Drug developer's shares  PHGE.A  rise 7.4% to $6.30
premarket
    ** Company enters collaboration with privately held
Boehringer Ingelheim to use PHGE's platform to potentially
identify biomarkers in patients with inflammatory bowel disease
 urn:newsml:reuters.com:*:nBw7m9PZVa
    ** As part of agreement, Boehringer has option to negotiate
exclusive right to biomarkers discovered using PHGE's platform
    ** Up to Tuesday's close, PHGE down ~40% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463))